Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous Lymphoma—Inpatient Considerations

  • Hospital-based Dermatology (D Kroshinsky, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of review

This is an overview of the important considerations for hospitalized patients with primary cutaneous lymphoma (PCL). The evaluation and management of inpatients with a suspected or confirmed diagnosis of PCL are discussed. Additionally, attention is paid to the complications associated with therapy for PCL that might warrant inpatient care.

Recent findings

There are many therapies that have demonstrated efficacy and safety in PCL patients. However, with new therapies also come serious complications associated with treatment. Furthermore, reviews and case studies have established the significant morbidity and mortality associated with the rapidly progressive clinical course of certain aggressive PCL variants. These findings have implications for the management of PCL patients.

Summary

For patients with PCL, it is important to consider the characteristics of their disease and their selected therapeutic regimen as both have implications for patient care. Optimal management of a hospitalized PCL patient requires a multi-disciplinary team of physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291–6. doi:10.1016/j.clml.2012.06.010.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.

    Article  CAS  PubMed  Google Scholar 

  3. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32. doi:10.1182/blood-2011-01-293050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin. 2015;33(4):643–54. doi:10.1016/j.det.2015.06.001.

    Article  CAS  PubMed  Google Scholar 

  5. Pinter-Brown LC. Diagnosis and management of cutaneous B-cell lymphoma. Dermatol Clin. 2015;33(4):835–40. doi:10.1016/j.det.2015.05.003.

    Article  CAS  PubMed  Google Scholar 

  6. Oluwole OO, Zic JA, Douds JJ, et al. Cutaneous manifestations and management of hematologic neoplasms. Semin Oncol. 2016;43(3):370–83. doi:10.1053/j.seminoncol.2016.02.021.

    Article  PubMed  Google Scholar 

  7. Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011;64(1):1–6. doi:10.1016/j.jdermsci.2011.07.007.

    Article  PubMed  Google Scholar 

  8. Mistry N, Gupta A, Alavi A, et al. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care 2015;28(5):228–236; quiz 37-8. doi:10.1097/01.ASW.0000463573.40637.73.

    Article  PubMed  Google Scholar 

  9. Tan GF, Kong YL, Tan AS, et al. Causes and features of erythroderma. Ann Acad Med Singap. 2014;43(8):391–4.

    PubMed  Google Scholar 

  10. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. doi:10.1182/blood-2007-03-055749.

    Article  CAS  PubMed  Google Scholar 

  11. DeFor TE, Majhail NS, Weisdorf DJ, et al. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(5):933–8. doi:10.1038/bmt.2009.275.

    Article  CAS  PubMed  Google Scholar 

  12. Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and Sézary syndrome. Dermatol Clin. 2015;33(4):807–18. doi:10.1016/j.det.2015.05.014.

    Article  CAS  PubMed  Google Scholar 

  13. de Masson A, Beylot-Barry M, Bouaziz J-D, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99(3):527–34.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5. doi:10.1093/annonc/mdv473.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Hughes CF, Newland K, McCormack C, et al. Mycosis fungoides and Sezary syndrome: current challenges in assessment, management and prognostic markers. Australas J Dermatol. 2016;57(3):182–91. doi:10.1111/ajd.12349.

    Article  PubMed  Google Scholar 

  16. Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–73. doi:10.1200/JCO.2015.61.7142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kubica AW, Davis MD, Weaver AL, et al. Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol. 2012;67(6):1189–99. doi:10.1016/j.jaad.2012.04.043.

    Article  PubMed  Google Scholar 

  18. Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi149–54. doi:10.1093/annonc/mdt242.

    Article  PubMed  Google Scholar 

  19. Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656–65. doi:10.1097/PAS.0b013e31826a5038.

    Article  PubMed  Google Scholar 

  20. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407–12. doi:10.1182/blood-2002-05-1597.

    Article  CAS  PubMed  Google Scholar 

  21. Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. Eur J Haematol. 2015;94(3):206–18. doi:10.1111/ejh.12439.

    Article  CAS  PubMed  Google Scholar 

  22. Anil R, Grover S, Hiremath A. A rare case of cutaneous gamma delta T-cell lymphoma with complete body involvement. J Med Cases. 2016;7(8):364–7.

    Article  Google Scholar 

  23. Chakrapani A, Avery A, Warnke R. Primary cutaneous gamma delta T-cell lymphoma with brain involvement and hemophagocytic syndrome. Am J Dermatopathol. 2013;35(2):270–2. doi:10.1097/DAD.0b013e3182624e98.

    Article  PubMed  Google Scholar 

  24. Harrington L, Sokol L, Holdener S, et al. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014;41(12):936–43. doi:10.1111/cup.12395.

    Article  PubMed  Google Scholar 

  25. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31. doi:10.1002/pbc.21039.

    Article  PubMed  Google Scholar 

  26. Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology. 2015;67(4):425–41. doi:10.1111/his.12371.

    Article  PubMed  Google Scholar 

  27. Kavishwar VS, Kirti C, Kush R, et al. Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a case report and significance of timely ancillary testing. Indian J Pathol Microbiol. 2016;59(1):131–2. doi:10.4103/0377-4929.174881.

    PubMed  Google Scholar 

  28. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–6. doi:10.1200/JCO.2011.35.6287.

    Article  CAS  PubMed  Google Scholar 

  29. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40(3):221–32.

    Article  PubMed  Google Scholar 

  30. Kheterpal M, Mehta-Shah N, Virmani P, et al. Managing patients with cutaneous B-cell and T-cell lymphomas other than mycosis fungoides. Curr Hematol Malig Rep. 2016;11(3):224–33. doi:10.1007/s11899-016-0322-5.

    Article  PubMed  Google Scholar 

  31. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144–50. doi:10.1001/archderm.143.9.1144.

    Article  PubMed  Google Scholar 

  32. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66. doi:10.1001/archderm.139.7.857.

    Article  PubMed  Google Scholar 

  33. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA. 1992;267(10):1354–8.

    Article  CAS  PubMed  Google Scholar 

  34. Willerslev-Olsen A, Krejsgaard T, Lindahl LM, et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel). 2013;5(8):1402–21. doi:10.3390/toxins5081402.

    Article  CAS  Google Scholar 

  35. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32–40.

    CAS  PubMed  Google Scholar 

  36. Torocsik D, Gergely L, Veres I, et al. Cutaneous cryptococcosis mimicking basal cell carcinoma in a patient with Sezary syndrome. Acta Derm Venereol. 2012;92(3):286–7. doi:10.2340/00015555-1326.

    Article  PubMed  Google Scholar 

  37. Aderhold K, Carpenter L, Brown K, et al. Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a rapidly progressive variant of cutaneous T-cell lymphoma. Case Rep Oncol Med. 2015;2015:429068. doi:10.1155/2015/429068.

    PubMed  PubMed Central  Google Scholar 

  38. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol. 2008;26(1):8–20. doi:10.1002/hon.836.

    Article  CAS  PubMed  Google Scholar 

  39. Tolkachjov SN, Weenig RH, Comfere NI. Cutaneous peripheral T-cell lymphoma, not otherwise specified: a single-center prognostic analysis. J Am Acad Dermatol. 2016; doi:10.1016/j.jaad.2016.06.011.

    Google Scholar 

  40. Tsai HJ, Lin SF, Chen CC, et al. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015;94(2):130–7. doi:10.1111/ejh.12405.

    Article  CAS  PubMed  Google Scholar 

  41. Itonaga H, Taguchi J, Fukushima T, et al. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. Biol Blood Marrow Transplant. 2013;19(4):607–15. doi:10.1016/j.bbmt.2013.01.011.

    Article  PubMed  Google Scholar 

  42. Aoki K, Arima H, Tabata S, et al. Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification. Ann Hematol. 2012;91(12):1975–6. doi:10.1007/s00277-012-1494-2.

    Article  PubMed  Google Scholar 

  43. Jamil A, Nadzri N, Harun N, et al. Primary cutaneous diffuse large B-cell lymphoma leg type presenting with hemophagocytic syndrome. J Am Acad Dermatol. 2012;67(5):e222–3. doi:10.1016/j.jaad.2012.04.021.

    Article  PubMed  Google Scholar 

  44. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600–9. doi:10.1182/blood-2008-04-152850.

    Article  CAS  PubMed  Google Scholar 

  45. Huen AO, Kim EJ. The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):715–29. doi:10.1016/j.det.2015.05.007.

    Article  CAS  PubMed  Google Scholar 

  46. Zinzani PL, Corradini P, Gallamini A, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma. 2012;53(5):789–95. doi:10.3109/10428194.2011.629701.

    Article  CAS  PubMed  Google Scholar 

  47. • de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720–4. doi:10.1111/bjd.12690. This multi-center retrospective analysis concluded that alemtuzumab demonstrates long-term efficacy in patients with Sézary Syndrome, but less so in patients with mycosis fungoides and transformed cutaneous T cell lymphoma. The analysis also found high rates of hematological and infectious adverse events associated with alemtuzumab therapy

    Article  PubMed  Google Scholar 

  48. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132(1):3–12. doi:10.1111/j.1365-2141.2005.05789.x.

    Article  PubMed  Google Scholar 

  49. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63. doi:10.1200/JCO.2013.52.0924.

    Article  CAS  PubMed  Google Scholar 

  50. Chung CG, Poligone B. Other chemotherapeutic agents in cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):787–805. doi:10.1016/j.det.2015.05.012.

    Article  CAS  PubMed  Google Scholar 

  51. Geskin LJ. Monoclonal antibodies. Dermatol Clin. 2015;33(4):777–86. doi:10.1016/j.det.2015.05.015.

    Article  CAS  PubMed  Google Scholar 

  52. Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71. doi:10.1002/cncr.28712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Duvic M. Histone deacetylase inhibitors for cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):757–64. doi:10.1016/j.det.2015.05.010.

    Article  CAS  PubMed  Google Scholar 

  54. Munster PN, Rubin EH, Van Belle S, et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009;15(22):7077–84. doi:10.1158/1078-0432.CCR-09-1214.

    Article  CAS  PubMed  Google Scholar 

  55. • Foss F, Advani R, Duvic M, et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–9. doi:10.1111/bjh.13222. This open-label, multi-center study demonstrated that belinostat monotherapy was effective in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma who had failed at least one prior systemic therapy. While belinostat was well tolerated overall, the study identified potentially serious adverse effects of treatment, including myelosuppression and fatal arrhythmias

    Article  CAS  PubMed  Google Scholar 

  56. Poole RM. Belinostat: first global approval. Drugs. 2014;74(13):1543–54. doi:10.1007/s40265-014-0275-8.

    Article  CAS  PubMed  Google Scholar 

  57. Zain J, Foss F, Kelly W, et al., editors. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. ASCO Annual Meeting Proceedings; 2009.

  58. Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386–94. doi:10.1016/j.ejca.2012.08.017.

    Article  CAS  PubMed  Google Scholar 

  59. Wood GS, Wu J. Methotrexate and pralatrexate. Dermatol Clin. 2015;33(4):747–55. doi:10.1016/j.det.2015.05.009.

    Article  CAS  PubMed  Google Scholar 

  60. Mna AB, Souissi A, Halouani S, et al. Methotrexate-induced necrolysis in tumoral-stage mycosis fungoides: a challenging diagnosis. Dermatol Online J. 2016;22(1).

  61. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–22. doi:10.1182/blood-2011-11-390211.

    Article  CAS  PubMed  Google Scholar 

  62. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19(2):377–88. doi:10.1007/s12350-012-9512-2.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10(2):132–9. doi:10.1067/mnc.2003.7.

    Article  PubMed  Google Scholar 

  64. Schadt CR. Topical and oral bexarotene. Dermatol Ther. 2013;26(5):400–3. doi:10.1111/dth.12087.

    Article  PubMed  Google Scholar 

  65. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168(1):192–200. doi:10.1111/bjd.12042.

    Article  CAS  PubMed  Google Scholar 

  66. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.

    Article  CAS  PubMed  Google Scholar 

  67. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.

    CAS  PubMed  Google Scholar 

  68. Zinzani PL, Bonthapally V, Huebner D, et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: cutaneous T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:228–40. doi:10.1016/j.critrevonc.2015.12.018.

    Article  PubMed  Google Scholar 

  69. Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center Leuk Lymphoma. 2009;50(12):1969–76. doi:10.3109/10428190903216770.

    Article  CAS  PubMed  Google Scholar 

  70. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267–72. doi:10.1182/blood-2002-09-2802.

    Article  CAS  PubMed  Google Scholar 

  71. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24. doi:10.1086/504811.

    Article  CAS  PubMed  Google Scholar 

  72. Hotz C, Ingen-Housz-Oro S, Tran Van Nhieu J, et al. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab. Eur J Dermatol. 2011;21(6):1018–20. doi:10.1684/ejd.2011.1538.

    CAS  PubMed  Google Scholar 

  73. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768–73. doi:10.1182/blood-2002-01-0159.

    Article  CAS  PubMed  Google Scholar 

  74. Karlsson C, Lundin J, Kimby E, et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol. 2009;144(1):78–85. doi:10.1111/j.1365-2141.2008.07451.x.

    Article  CAS  PubMed  Google Scholar 

  75. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784–94.

    Article  CAS  PubMed  Google Scholar 

  76. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104(3):655–8. doi:10.1182/blood-2003-07-2345.

    Article  CAS  PubMed  Google Scholar 

  77. Watanabe R, Teague JE, Fisher DC, et al. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150(7):776–9. doi:10.1001/jamadermatol.2013.10099.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood. 2005;105(10):4148–9. doi:10.1182/blood-2004-11-4314.

    Article  CAS  PubMed  Google Scholar 

  79. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–4. doi:10.1182/blood-2003-10-3389.

    Article  CAS  PubMed  Google Scholar 

  80. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9. doi:10.1182/blood-2014-09-600924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. doi:10.1200/JCO.2011.37.3472.

    Article  CAS  PubMed  Google Scholar 

  82. Ishida T, Ito A, Sato F, et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer Sci. 2013;104(5):647–50. doi:10.1111/cas.12116.

    Article  CAS  PubMed  Google Scholar 

  83. • Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65. doi:10.1200/JCO.2014.60.3787. This phase II open-label trial provides evidence that brentuximab therapy is safe and effective for the treatment of CD30 + cutaneous T cell lymphoma, including lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and mycosis fungoides (MF). The results also demonstrated that CD30 expression among patients with MF did not correlate with response, but relapse of lesions appeared to be more commonly associated with low CD30 expression

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. • Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8. doi:10.1200/JCO.2014.60.3969. This phase II study demonstrated that brentuximab produces a response in treatment-refractory or advanced mycosis fungoides or Sézary Syndrome with variable CD30 expression levels

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Saintes C, Saint-Jean M, Renaut JJ, et al. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression. Br J Dermatol. 2015;172(3):819–21. doi:10.1111/bjd.13337.

    Article  CAS  PubMed  Google Scholar 

  86. Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015;170(1):96–109. doi:10.1111/bjh.13400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Kim M, Thompson LA, Wenger SD, et al. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Ann Pharmacother. 2012;46(10):1340–8. doi:10.1345/aph.1R036.

    Article  PubMed  Google Scholar 

  88. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. doi:10.1182/blood-2010-10-312603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412–6. doi:10.3816/CLM.2009.n.082.

    Article  PubMed  Google Scholar 

  90. Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: a review of clinical studies. Cancer Treat Rev. 2016;43:58–66. doi:10.1016/j.ctrv.2015.04.003.

    Article  CAS  PubMed  Google Scholar 

  91. • Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2:16. doi:10.1186/2050-7771-2-16. This analysis evaluated the adverse event profile associated with romidepsin therapy in patients with relapsed/refractory peripheral (PTCL) and cutaneous T cell lymphoma (CTCL). The results demonstrated that the most common adverse events were hematologic toxicities, infectious, and electrocardiogram abnormalities. Patients with PTCL appeared to experience more frequent and more severe adverse events than patients with CTCL

    Article  PubMed  PubMed Central  Google Scholar 

  92. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15. doi:10.1200/JCO.2006.10.2434.

    Article  CAS  PubMed  Google Scholar 

  93. Kakar R, Rommel J, McKinley-Grant L, et al. Hypersensitivity to romidepsin. J Am Acad Dermatol. 2014;70(1):e21–2. doi:10.1016/j.jaad.2013.09.040.

    Article  PubMed  Google Scholar 

  94. Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6(4):202–8. doi:10.1177/2040620715592567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Steward JS, Bullard HM, O’Rourke TJ, et al. Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma. J Oncol Pharm Pract. 2016; doi:10.1177/1078155216665244.

    PubMed  Google Scholar 

  96. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873–8. doi:10.1067/S0190.

    Article  PubMed  Google Scholar 

  97. Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81. doi:10.1182/blood-2014-07-588236.

    Article  CAS  PubMed  Google Scholar 

  98. Olsen EA, Rook AH, Zic J, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352–404. doi:10.1016/j.jaad.2010.08.037.

    Article  PubMed  Google Scholar 

  99. Marrone LC, Marrone BF, de la Puerta RJ, et al. Gemcitabine monotherapy associated with posterior reversible encephalopathy syndrome. Case Rep Oncol. 2011;4(1):82–7. doi:10.1159/000324581.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 777 South Eden Street Apt 1031, Baltimore, MD, 21231, USA

    Kerry Heitmiller

  2. 55 Fruit Street, Yawkey 9A, Boston, MA, 02114, USA

    Jeffrey Barnes

  3. 50 Staniford Street, 2nd Floor, Boston, MA, 02114, USA

    Steven T. Chen

Authors
  1. Kerry Heitmiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven T. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven T. Chen.

Ethics declarations

Conflict of Interest

Kerry Heitmiller, Jeffrey Barnes and Steven Chen declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hospital-based Dermatology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heitmiller, K., Barnes, J. & Chen, S.T. Cutaneous Lymphoma—Inpatient Considerations. Curr Derm Rep 6, 63–76 (2017). https://doi.org/10.1007/s13671-017-0173-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-017-0173-x

Keywords

Search

Navigation